Form 4 for LYEL Lyell Immunopharma, Inc.
Accepted 2026-02-11 00:00:00 ET · period of report 2026-02-09 · accession 0001866154-26-000001 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-02-11 | 2026-02-09 | LYEL | Hill Stephen J. | COO | A - Grant | $0.00 | +4,000 | 19.1K | +26% | $0 |
| D | 2026-02-11 | 2026-02-10 | LYEL | Hill Stephen J. | COO | S - Sale | $23.12 | -109 | 19.0K | -0.6% | -$2,520 |
| D | 2026-02-11 | 2026-02-10 | LYEL | Hill Stephen J. | COO | A - Grant | $0.00 | +65.0K | 65.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-09 | A | A | 4,000 | $0.00 | 19,140 | D | — | — | (F1) Pursuant to performance-based restricted stock units granted to the reporting person on February 9, 2024, 4,000 shares were issued on the Transaction Date upon the achievement of certain performance criteria certified by the compensation committee of the Issuer's board of directors on the Transaction Date. (F2) Includes 390 shares acquired on November 18, 2025 under the Issuer's 2021 Employee Stock Purchase Plan. |
| 2 | Common | Common Stock | 2026-02-10 | S | D | 109 | $23.12 | 19,031 | D | — | — | (F3) Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units. |
| 3 | Derivative | Option (right to buy) | 2026-02-10 | A | A | 65,000 | $0.00 | 65,000 | D | $23.71 · — to 2036-02-09 | 65,000 Common Stock | (F4) Twelve and one-half percent (12.5%) of the total number of shares of Common Stock subject to the option will be vested and exercisable on the date that is six (6) months after February 9, 2026 (the "Vesting Commencement Date") and thereafter, an additional one fortyeighth (1/48th) of the shares will become vested and exercisable monthly on the same day as the Vesting Commencement Date (or, if there is no such corresponding day for a given month, on the last day of such month), until the option has become vested and exercisable with respect to one hundred percent (100%) of the shares, subject to the Reporting Person providing service to the Issuer through each applicable vesting date. |